NovaBridge Biosciences Accounts Payable and Accrued Liabilities
NovaBridge Biosciences (NBP) had Accounts Payable and Accrued Liabilities of $7.64 million as of 2024-12-31, per its 20-F filed 2025-04-03.
Financial Statements › Balance Sheet › Liabilities
us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent · last filed 2025-04-03
- 2023-12-31: Accounts Payable and Accrued Liabilities 427.42M CNY.
- 2022-12-31: Accounts Payable and Accrued Liabilities 723.53M CNY.
- 2022-06-30: Accounts Payable and Accrued Liabilities 561.42M CNY.
- 2021-12-31: Accounts Payable and Accrued Liabilities 608.27M CNY.
CNY
| Period end | Accounts Payable and Accrued Liabilities |
|---|---|
| 2023-12-31 | 427.42M CNY 20-F · filed 2024-04-30 |
| 2022-12-31 | 723.53M CNY 20-F · filed 2024-04-30 |
| 2022-06-30 | 561.42M CNY 6-K · filed 2022-11-10 |
| 2021-12-31 | 608.27M CNY 20-F · filed 2023-05-01 |
| 2020-12-31 | 569.53M CNY 20-F · filed 2022-04-29 |
USD
| Period end | Accounts Payable and Accrued Liabilities | Accounts Payable and Accrued Liabilities as first filed |
|---|---|---|
| 2024-12-31 | $7.64M 20-F · filed 2025-04-03 | |
| 2023-12-31 | $7.96M 20-F · filed 2025-04-03 | $60.20M 20-F · filed 2024-04-30 |
| 2022-12-31 | $104.90M 20-F · filed 2023-05-01 | |
| 2022-06-30 | $83.82M 6-K · filed 2022-11-10 | |
| 2021-12-31 | $95.45M 20-F · filed 2022-04-29 | |
| 2020-12-31 | $87.28M 20-F · filed 2021-04-28 |